Roth Capital Has Negative Outlook for Enovis FY2025 Earnings

Enovis Co. (NYSE:ENOV) – Stock analysts at Roth Capital cut their FY2025 earnings estimates for shares of Enovis in a report released on Thursday, February 27th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $3.24 per share for the year, down from their previous forecast of $3.31. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ FY2026 earnings at $3.74 EPS.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million.

Separately, Needham & Company LLC decreased their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday.

Enovis Stock Up 1.4 %

Shares of ENOV opened at $38.67 on Friday. Enovis has a 52 week low of $37.60 and a 52 week high of $63.96. The firm has a market cap of $2.20 billion, a P/E ratio of -17.66 and a beta of 1.94. The firm’s 50-day simple moving average is $44.72 and its 200 day simple moving average is $44.27. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Quadrant Capital Group LLC grew its position in shares of Enovis by 53.0% during the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after purchasing an additional 239 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Enovis by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock worth $1,136,000 after acquiring an additional 264 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares during the period. Arizona State Retirement System lifted its holdings in shares of Enovis by 2.6% during the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock worth $711,000 after acquiring an additional 414 shares during the period. Finally, Aigen Investment Management LP lifted its holdings in shares of Enovis by 5.1% during the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock worth $381,000 after acquiring an additional 430 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.